ASCO 2025: Vepdegestrant's Efficacy and Safety in ER+/HER2- Advanced Breast CancerByGillian McGovern, Associate Editor,Erika Hamilton, MDJune 2nd 2025Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.